Testimonials
"Working with Sabine has been a great experience. She provided us with detailed and accurate preclinical modeling that helped us to make informed decisions regarding our product development. I was impressed with her of professionalism and her commitment to delivering high-quality results."
Pharma client
"I worked with Sabine to predict a human dose and pharmacokinetic profile for one of our biotech company's therapeutic programs. She was very detail oriented and comprehensive in her analyses and modeling in addition to being a pleasure to work with. I would not hesitate to engage with her again."
CEO of biotech company
Journal Publications
Rauh, U., Wei, G., Serrano-Wu, M., Kosmidis, G., Kaulfuss, S., Siegel, F., Thede, K., McFarland, J., Lemke, C., Werbeck, N., Nowak-Reppel, K., Pilari, S., Menz, S., Ocker, M., Kaushik, V., Ziegelbauer, K., Golub, T. (2024). BRD-810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature Cancer, 5, 1479–1493.
​
Graham, K., Lienau, P., Bader, B., Prechtl, S., Naujoks, J., Lesche, R., Weiske, J., Kuehnlenz, J., Brzezinka, K., Potze, L., Zanconato, F., Nicke, B., Montebaur, A., Bone, W., Golfier, S., Kaulfuss, S., Kopitz, C., Pilari, S., Steuber, H., Hayat, S., Kamburov, A., Steffen, A., Schlicker, A., Buchgraber, P., Braeuer, N., Font, N.A., Heinrich, T., Kuhnke, L., Nowak-Reppel, K., Stresemann, C., Steigemann, P., Walter, A.O., Blotta, S., Ocker, M., Lakner, A., Mumberg, D., Eis, K., Piccolo, S., Lange, M. (2023). Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling. bioRvix, preprint.
​​​
Pilari, S., Gaub, T., Block, M., & Görlitz, L. (2017). Development of physiologically based organ models to evaluate the pharmacokinetics of drugs in the testes and the thyroid gland. CPT: pharmacometrics & systems pharmacology, 6(8), 532-542.
​
Fronton, L., Pilari, S., & Huisinga, W. (2014). Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. Journal of pharmacokinetics and pharmacodynamics, 41, 87-107.
​
Huisinga, W., Solms, A., Fronton, L., & Pilari, S. (2012). Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT: pharmacometrics & systems pharmacology, 1(9), 1-10.
​​​
Pilari, S., Preuße, C., & Huisinga, W. (2011). Gestational influences on the pharmacokinetics of gestagenic drugs: a combined in silico, in vitro and in vivo analysis. European journal of pharmaceutical sciences, 42(4), 318-331.
​​​
Pilari, S., & Huisinga, W. (2010). Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. Journal of pharmacokinetics and pharmacodynamics, 37, 365-405.